Literature DB >> 21336872

Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures.

Alberto M Davalli1, Carla Perego, Franco B Folli, Emanuele Bosi.   

Abstract

We report a case of unusually long-lasting remission of type 1 diabetes (T1D). The patient, a Caucasian man, at the age of 43 years developed a ketotic diabetes, classified as type 1 based on clinical presentation and positivity for islet autoantibodies. Shortly after diabetes onset, oral topiramate was added to preexisting valproic acid for generalized seizures and maintained thereafter. Initial intensive insulin treatment was rapidly reduced to low doses (3 Units/day) maintained for a long time and then discontinued at month 55; fasting glucose and glycosylated hemoglobin were basically normalized at 58 months. An oral glucose tolerance test performed at month 53 showed an impaired fasting glucose (6.0 mmol/l) and a value slightly above the threshold for the diagnosis of diabetes at 2 h (11.2 mmol/l). We hypothesize that this unusually prolonged preservation of β-cell function might be ascribed to the concomitant therapy with topiramate, an antiepileptic agent with demonstrated efficacy as antidiabetic in type 2 diabetes (T2D). Topiramate should be further investigated as candidate agent for the preservation of β-cell function also in T1D.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336872     DOI: 10.1007/s00592-011-0268-y

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  3 in total

1.  CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.

Authors:  Andrew D Vonberg; Maria Acevedo-Calado; Aaron R Cox; Susan L Pietropaolo; Roberto Gianani; Steven K Lundy; Massimo Pietropaolo
Journal:  JCI Insight       Date:  2018-12-06

2.  Testing agents for prevention or reversal of type 1 diabetes in rodents.

Authors:  Christian W Grant; Catherine M Moran-Paul; Shane K Duclos; Dennis L Guberski; Guillermo Arreaza-Rubín; Lisa M Spain
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

3.  Carbamazepine, a beta-cell protecting drug, reduces type 1 diabetes incidence in NOD mice.

Authors:  Jason T C Lee; Iryna Shanina; Yung Ning Chu; Marc S Horwitz; James D Johnson
Journal:  Sci Rep       Date:  2018-03-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.